SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that it has initiated a first-in-human Phase 1 clinical study of ACCG-2671, the company’s lead oral small molecule amylin receptor agonist for the treatment of obesity. ACCG-2671 was designed via the company’s next generation structure-based drug discove ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The GLP-1 class of drugs has become a revolutionary therapy in the weight loss field, transitioning from an "adjunctive" role to a "core medication" status, significantly improving metabolic indicators while effectively reducing weight [19][20] - Multiple companies have disclosed promising weight loss data, with a focus on domestic companies such as Federated Pharmaceutical, Lepu Medical, and Greeley Pharmaceuticals [2][19] - The report highlights the potential of oral small molecule GLP-1 drugs, with significant clinical data from companies like Greeley Pharmaceuticals and Structure Therapeutics [21][22] Summary by Sections Investment Highlights - The report emphasizes the growth potential in the weight loss drug market, driven by drugs like Semaglutide and Tirzepatide, with notable clinical results from various companies [2][19] - The report suggests monitoring the development of domestic small nucleic acid drugs, which have shown promising results in reducing visceral fat and increasing lean body mass [2] Sub-industry Rankings - The report ranks sub-industries in the following order: Innovative Drugs > Research Services > CXO > Traditional Chinese Medicine > Medical Devices > Pharmacies [3][12] - Specific stock recommendations include Federated Pharmaceutical, Lepu Medical, and Greeley Pharmaceuticals from the GLP perspective, and companies like 3SBio, Kintor Pharmaceutical, and Innovent Biologics from the PD1/VEGF dual antibody perspective [3][15] Market Performance - The A-share pharmaceutical index has shown a year-to-date increase of 14.65%, while the Hang Seng Biotechnology Index has increased by 77.09% [11] - The report notes that the medical services sector has seen a price increase of 1.67%, while other sectors like chemical pharmaceuticals and medical devices have experienced declines [11] Clinical Development Updates - Greeley Pharmaceuticals' ASC30 achieved a 7.7% weight reduction in a 13-week study, while Structure Therapeutics' Aleniglipron showed a 15.3% reduction in a 36-week study [21][22] - The report highlights the competitive landscape of oral GLP-1 drugs, with Greeley's ASC30 demonstrating superior weight loss effects compared to Eli Lilly's Orforglipron [23]

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the closing of its previously announced upsized underwritten public offering of 9,961,538 American depositary shares (ADSs), each representing three ordinary shares, which includes the full exercise of the underwriters’ option to purchase up to 1,500,000 ...

智通财经APP获悉，周三，美股减肥药概念股走强，截至发稿，硕迪生物(GPCR.US)涨超5%，诺和诺德 (NVO.US)涨超3.5%，罗氏(RHHBY.US)涨超3%，礼来(LLY.US)微涨。消息面上，此前硕迪生物公布其 每日一次、口服小分子GLP-1受体激动剂aleniglipron在ACCESS临床项目中取得积极顶线结果。 ...

Core Insights - Structure Therapeutics announced positive results from its oral GLP-1 receptor agonist aleniglipron in the ACCESS clinical trial, showing significant weight loss in overweight and obese adults with related complications [4][6] - The ACCESS II study demonstrated a maximum placebo-adjusted average weight loss of 15.3% with a 240mg dose, indicating the drug's tolerability aligns with GLP-1 class characteristics [6] - The company plans to engage with the FDA for a Type B meeting in the first half of next year to finalize the Phase III study protocol [6] Group 1: Clinical Trial Results - In the core IIb ACCESS study, participants receiving 120mg of aleniglipron achieved an average weight loss of 11.3% after 36 weeks, with a 10.4% rate of treatment discontinuation due to adverse events [4] - Among the 120mg group, 86% of participants lost at least 5% of their body weight, and 70% achieved over 10% weight loss [4] - The ACCESS open-label extension results indicated sustained weight loss up to 44 weeks, with improved tolerability when starting at a lower 2.5mg dose [6] Group 2: Safety and Tolerability - No drug-related liver injury, persistent liver enzyme elevation, or QTc prolongation was observed across all studies [6] - An exploratory study with a lower starting dose of 2.5mg showed improved tolerability without any treatment discontinuation due to adverse events during the initial dosing phase [6] Group 3: Future Plans and Market Potential - CEO Raymond Stevens highlighted that the latest results demonstrate aleniglipron's differentiated characteristics, offering clinically meaningful and competitive weight loss with safety suitable for chronic treatment [6] - The drug presents new treatment hope for millions of patients struggling with obesity and related complications [6]

Core Viewpoint - Structure Therapeutics Inc. has announced the pricing of its upsized public offering of American depositary shares (ADSs) aimed at raising approximately $650 million to support its development of novel oral small molecule therapeutics for metabolic diseases, particularly obesity [1][2]. Offering Details - The offering consists of 8,461,538 ADSs priced at $65.00 each and pre-funded warrants for 1,538,462 ADSs priced at $64.9999 each [1]. - The gross proceeds from the offering are expected to be around $650 million before deducting underwriting discounts and commissions [2]. - Structure Therapeutics has granted underwriters a 30-day option to purchase an additional 1,500,000 ADSs at the public offering price [2]. Underwriters - Jefferies, Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley, Guggenheim Securities, and BMO Capital Markets are acting as joint book-running managers for the offering [3]. Regulatory Information - The offering is made under an automatic shelf registration statement on Form S-3 filed with the SEC on August 6, 2025, which became effective upon filing [4]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available for free on the SEC's website [4]. Company Overview - Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs [6]. - The company utilizes a next-generation structure-based drug discovery platform and has established a robust GPCR-targeted pipeline featuring multiple proprietary clinical-stage oral small molecule compounds [6].

We recently published 10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to a new 52-week high on Monday after announcing stellar topline results from its ongoing clinical program to test the efficacy of its therapy candidate, aleniglipron, in obese patients with co-morbidity. At intra-day trading, the stock surged to its highest price of $94.90 before profit-taking persisted and tr ...

Core Insights - Structure Therapeutics' shares surged 102.5% following positive top-line data from the ACCESS clinical program for aleniglipron, an investigational GLP-1 RA aimed at treating obesity and overweight patients with co-morbidities [1][3] - The 36-week phase IIb ACCESS study showed a placebo-adjusted mean weight reduction of 11.3% (27.3 lbs) at the highest 120 mg dose, meeting primary and secondary endpoints [3][4] - The ongoing ACCESS II study indicated even greater weight loss, with a 15.3% (35.5 lbs) reduction at the 240 mg dose, and sustained weight reduction observed through 44 weeks in the ACCESS OLE study [4][6] Company Developments - Structure Therapeutics plans to advance aleniglipron into phase III development, with a Type B end-of-phase 2 meeting with the FDA expected in the first half of 2026 [8][9] - The phase III study design will include a lower 2.5 mg starting dose and multiple dose levels up to 240 mg [9] - The company is also developing ANPA-0073, a phase II-ready APJR agonist for selective weight loss, alongside other obesity drug candidates in preclinical stages [10] Competitive Landscape - Eli Lilly and Novo Nordisk dominate the obesity treatment market, with their drugs Zepbound and Wegovy, respectively, experiencing stock declines following GPCR's positive results [12] - The U.S. obesity market is projected to reach $100 billion by 2030, prompting major players to optimize production and develop more effective GLP-1-based candidates [13] - Novo Nordisk is pursuing an oral version of Wegovy, while Eli Lilly is advancing several new molecules, including orforglipron and retatrutide, with regulatory applications expected soon [14][15]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive an ...

The company's investigational GLP-1 treatment performed admirably well in a phase 2b study.Monday was quite the day for biotech companies developing the next generation of obesity drugs. One of them, Structure Therapeutics (GPCR +102.49%), skyrocketed almost 103% higher in price that day on some highly promising data produced by its weight-loss candidate medication. A successful studyStructure, which concentrates on metabolic diseases with a particular focus on obesity, unveiled the topline data for its GLP ...